Gapping up
In reaction to earnings/guidance:
- JPM +1.4% (provides guidance at investor day)
Other news:
- GOEV +6.5% (files for 48043111 share common stock offering by selling shareholder)
- GLSI +5.6% (to resume stock repurchase program)
- AXL +5.2% (provides statement on company sale speculation)
- GNK +5% (positive Barrons article)
- NEXT +4.7% (files for 4618226 share common stock offering by selling shareholder)
- CMPS +4.7% (COMPASS Pathways presents largest ever study of psilocybin therapy at American Psychiatric Association annual meeting)
- PSN +3.4% (entered into a definitive agreement to acquire Xator Corporation in a transaction valued at $400 mln)
- EA +2.6% (positive Barrons article)
- GH +2.1% (Presents New Data Showing Blood Test Accuracy in Detecting Colorectal Cancer in First-of-its Kind Prospective Study at Digestive Disease Week 2022)
- BNTX +1.9% (Pfizer/BioNTech (BNTX) COVID-19 vaccine demonstrates strong immune response high efficacy and favorable safety in children 6 months to under 5 years of age following third dose)
- POSH +1.8% (positive Barrons article)
- OCN +1.7% (Board of Directors authorizes $50 million share repurchase program)
- VG +1% (announces that termination date of previously announced deal for ERIC to acquire VG has been extended to August 22)
- RIVN +1% (positive Barrons article)
Analyst comments:
- MSI +2.6% (upgraded to Overweight from Equal-Weight at Morgan Stanley)
- THS +2.6% (upgraded to Buy from Hold at Truist)
- ZBRA +1.6% (upgraded to Equal-Weight from Underweight at Morgan Stanley)
- ED +1.5% (upgraded to Neutral from Sell at Guggenheim)
- TRMB +1.1% (upgraded to Equal-Weight from Underweight at Morgan Stanley)